DA
SYRS

Denali Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Denali Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,700
Closed -$27.6K – 499
2022
Q4 		$27.6K Buy
+7,700
New +$33.4K 0.01% 282

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Denali Advisors's SYRS Position: Q1 2023 in Review

Denali Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 7,700 shares — an estimated $27.6K sold.

Denali Advisors first reported a position in SYRS in Q4 2022 and held it in 1 quarter. The position peaked at $27.6K in Q4 2022. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

  • Denali Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Denali Advisors sold 7,700 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $27.6K.
  • Denali Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Denali Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $27.6K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Denali Advisors's 13F filing for Q1 2023, filed 21 Apr 2023.